Long-term survival in transfusion recipients in Sweden, 1993

被引:35
作者
Tynell, E [1 ]
Norda, R
Shanwell, A
Björkman, A
机构
[1] Karolinska Hosp, Div Infect Dis, S-17176 Stockholm, Sweden
[2] Soder Sjukhuset, Div Transfus Med, S-10064 Stockholm, Sweden
[3] Orebro Med Ctr Hosp, Dept Transfus Med & Immunohemotherapy, Orebro, Sweden
关键词
D O I
10.1046/j.1537-2995.2001.41020251.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Survival and characteristics of transfusion recipients have not been studied enough, although they represent key measures in cost-effectiveness analyses of various donor screening procedures. STUDY DESIGN AND METHODS: Hospital and blood bank records were collected on all patients in Orebro County, Sweden, from March through May 1993 (1111 transfusion episodes) and a random sample from Stockholm County during April 1993 (793 transfusion episodes). All patients were then matched with the national register of deaths in Sweden during a follow-up period of 40 months. RESULTS: The median patient age was 71 years and the median transfusion total was 2 units. Only 35 percent of the patients were under the age of 65, 9 percent under 40, and 1.6 percent under 1 year. About half (56%) were women. Among the Orebro patients, 47 percent were surgical and 29 percent internal medicine patients. Of 1720 patients whose survival could be investigated, 66 percent were alive after 1 year and 51 percent after 40 months. The survival rates were rather similar in patients receiving RBCs and plasma but lower in those receiving platelets. CONCLUSION: The survival of patients transfused in Sweden in 1993 differered significantly from estimations based on studies from the 1980s. This difference has major implications for the estimations of cost-effectiveness of blood donor screening for infectious agents.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 16 条
[1]  
AuBuchon J P, 1996, Am J Med, V101, p38S, DOI 10.1016/S0002-9343(96)00163-5
[2]   Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood [J].
AuBuchon, JP ;
Birkmeyer, JD ;
Busch, MP .
TRANSFUSION, 1997, 37 (01) :45-51
[3]   PREVALENCE OF ANTIBODIES TO HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN BLOOD-DONORS IN NORTH LONDON [J].
BRENNAN, M ;
RUNGANGA, J ;
BARBARA, JAJ ;
CONTRERAS, M ;
TEDDER, RS ;
GARSON, JA ;
TUKE, PW ;
MORTIMER, PP ;
MCALPINE, L ;
TOSSWILL, JHC .
BRITISH MEDICAL JOURNAL, 1993, 307 (6914) :1235-1239
[4]   Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections [J].
Busch, MP ;
Dodd, RY ;
Lackritz, EM ;
AuBuchon, JP ;
Birkmeyer, JD ;
Petersen, LR .
TRANSFUSION, 1997, 37 (10) :1003-1011
[5]   Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection [J].
Busch, MP ;
Korelitz, JJ ;
Kleinman, SH ;
Lee, SR ;
AuBuchon, JP ;
Schreiber, GB ;
Williams, AE ;
Ownby, HE ;
Waxman, DA ;
Hutching, S ;
Murphy, EL ;
Gilcher, RO ;
Smith, JW ;
Thomson, RA ;
Nemo, GJ ;
Zuck, TF .
TRANSFUSION, 1995, 35 (11) :903-910
[6]   BUFFY-COAT-DERIVED PLATELET CONCENTRATES PREPARED FROM HALF-STRENGTH CITRATE CPD AND CPD WHOLE-BLOOD UNITS - COMPARISON BETWEEN 3 ADDITIVE SOLUTIONS - IN-VITRO STUDIES [J].
GULLIKSSON, H ;
ERIKSSON, L ;
HOGMAN, CF ;
PAYRAT, JM .
VOX SANGUINIS, 1995, 68 (03) :152-159
[7]  
Littenberg B, 1995, Immunohematology, V11, P88
[8]  
PERKINS HA, 1987, BLOOD, V70, P1604
[9]  
PILLONEL J, 1995, J ACQ IMMUN DEF SYND, V10, P152
[10]   LONG-TERM MORTALITY AFTER TRANSFUSION-ASSOCIATED NON-A-HEPATITIS, NON-B-HEPATITIS [J].
SEEFF, LB ;
BUSKELLBALES, Z ;
WRIGHT, EC ;
DURAKO, SJ ;
ALTER, HJ ;
IBER, FL ;
HOLLINGER, FB ;
GITNICK, G ;
KNODELL, RG ;
PERRILLO, RP ;
STEVENS, CE ;
HOLLINGSWORTH, CG .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1906-1911